Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2019 - 2026)

Mirum Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $48.3 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 247.17% year-over-year to $48.3 million in Q1 2026; TTM through Mar 2026 was $48.3 million, a 247.17% increase from a year earlier, with the FY2024 full-year figure at $2.5 million, down 34.81% from the prior year.
• Other Non-Current Liabilities climbed to $48.3 million in Q1 2026 per MIRM's latest filing, from $16.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $138.0 million in Q3 2022 and bottomed at $1.1 million in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $4.4 million (2022), against an average of $27.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 726305.26% in 2022 and slumped 99.18% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $4.5 million in 2022, then dropped by 15.07% to $3.8 million in 2023, then sank by 34.81% to $2.5 million in 2024, then jumped by 536.95% to $16.0 million in 2025, then soared by 201.96% to $48.3 million in 2026.
• Per Business Quant, the three latest MIRM Other Non-Current Liabilities figures stand at $48.3 million (Q1 2026), $16.0 million (Q3 2025), and $9.1 million (Q2 2025).